328 related articles for article (PubMed ID: 16989930)
1. Comparison of lanosterol-14 alpha-demethylase (CYP51) of human and Candida albicans for inhibition by different antifungal azoles.
Trösken ER; Adamska M; Arand M; Zarn JA; Patten C; Völkel W; Lutz WK
Toxicology; 2006 Nov; 228(1):24-32. PubMed ID: 16989930
[TBL] [Abstract][Full Text] [Related]
2. Quantitation of lanosterol and its major metabolite FF-MAS in an inhibition assay of CYP51 by azoles with atmospheric pressure photoionization based LC-MS/MS.
Trösken ER; Straube E; Lutz WK; Völkel W; Patten C
J Am Soc Mass Spectrom; 2004 Aug; 15(8):1216-21. PubMed ID: 15276168
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of the heterologously expressed human lanosterol 14alpha-demethylase (other names: P45014DM, CYP51, P45051) and inhibition of the purified human and Candida albicans CYP51 with azole antifungal agents.
Lamb DC; Kelly DE; Waterman MR; Stromstedt M; Rozman D; Kelly SL
Yeast; 1999 Jun; 15(9):755-63. PubMed ID: 10398344
[TBL] [Abstract][Full Text] [Related]
4. Differential inhibition of human CYP3A4 and Candida albicans CYP51 with azole antifungal agents.
Lamb DC; Kelly DE; Baldwin BC; Kelly SL
Chem Biol Interact; 2000 Mar; 125(3):165-75. PubMed ID: 10731517
[TBL] [Abstract][Full Text] [Related]
5. Comparative assessment of the inhibition of recombinant human CYP19 (aromatase) by azoles used in agriculture and as drugs for humans.
Trösken ER; Scholz K; Lutz RW; Völkel W; Zarn JA; Lutz WK
Endocr Res; 2004 Aug; 30(3):387-94. PubMed ID: 15554355
[TBL] [Abstract][Full Text] [Related]
6. Structural analyses of
Hargrove TY; Friggeri L; Wawrzak Z; Qi A; Hoekstra WJ; Schotzinger RJ; York JD; Guengerich FP; Lepesheva GI
J Biol Chem; 2017 Apr; 292(16):6728-6743. PubMed ID: 28258218
[TBL] [Abstract][Full Text] [Related]
7. Azole affinity of sterol 14α-demethylase (CYP51) enzymes from Candida albicans and Homo sapiens.
Warrilow AG; Parker JE; Kelly DE; Kelly SL
Antimicrob Agents Chemother; 2013 Mar; 57(3):1352-60. PubMed ID: 23274672
[TBL] [Abstract][Full Text] [Related]
8. Novel antifungal agents which inhibit lanosterol 14alpha-demethylase in Candida albicans CCH442.
Zakula D; Capobianco JO; Goldman RC
J Antimicrob Chemother; 1997 Feb; 39(2):261-4. PubMed ID: 9069550
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human CYP19 by azoles used as antifungal agents and aromatase inhibitors, using a new LC-MS/MS method for the analysis of estradiol product formation.
Trösken ER; Fischer K; Völkel W; Lutz WK
Toxicology; 2006 Feb; 219(1-3):33-40. PubMed ID: 16330141
[TBL] [Abstract][Full Text] [Related]
10. Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14 alpha-sterol demethylase purified from Candida albicans.
Hitchcock CA; Dickinson K; Brown SB; Evans EG; Adams DJ
Biochem J; 1990 Mar; 266(2):475-80. PubMed ID: 2180400
[TBL] [Abstract][Full Text] [Related]
11. Molecular modelling of lanosterol 14 alpha-demethylase (CYP51) from Saccharomyces cerevisiae via homology with CYP102, a unique bacterial cytochrome P450 isoform: quantitative structure-activity relationships (QSARs) within two related series of antifungal azole derivatives.
Lewis DF; Wiseman A; Tarbit MH
J Enzyme Inhib; 1999; 14(3):175-92. PubMed ID: 10445042
[TBL] [Abstract][Full Text] [Related]
12. The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme.
Warrilow AG; Hull CM; Parker JE; Garvey EP; Hoekstra WJ; Moore WR; Schotzinger RJ; Kelly DE; Kelly SL
Antimicrob Agents Chemother; 2014 Dec; 58(12):7121-7. PubMed ID: 25224009
[TBL] [Abstract][Full Text] [Related]
13. A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals.
Ji H; Zhang W; Zhou Y; Zhang M; Zhu J; Song Y; Lü J
J Med Chem; 2000 Jun; 43(13):2493-505. PubMed ID: 10891108
[TBL] [Abstract][Full Text] [Related]
14. Differential inhibition of Candida albicans CYP51 with azole antifungal stereoisomers.
Lamb DC; Kelly DE; Baldwin BC; Gozzo F; Boscott P; Richards WG; Kelly SL
FEMS Microbiol Lett; 1997 Apr; 149(1):25-30. PubMed ID: 9103974
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of cytochrome P450 14alpha -sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors.
Podust LM; Poulos TL; Waterman MR
Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3068-73. PubMed ID: 11248033
[TBL] [Abstract][Full Text] [Related]
16. Improved model of lanosterol 14alpha-demethylase by ligand-supported homology modeling: validation by virtual screening and azole optimization.
Sheng C; Wang W; Che X; Dong G; Wang S; Ji H; Miao Z; Yao J; Zhang W
ChemMedChem; 2010 Mar; 5(3):390-7. PubMed ID: 20157915
[TBL] [Abstract][Full Text] [Related]
17. Molecular design of two sterol 14alpha-demethylase homology models and their interactions with the azole antifungals ketoconazole and bifonazole.
Rupp B; Raub S; Marian C; Höltje HD
J Comput Aided Mol Des; 2005 Mar; 19(3):149-63. PubMed ID: 16059669
[TBL] [Abstract][Full Text] [Related]
18. Cloning and characterization of CYP51 from Mycobacterium avium.
Pietila MP; Vohra PK; Sanyal B; Wengenack NL; Raghavakaimal S; Thomas CF
Am J Respir Cell Mol Biol; 2006 Aug; 35(2):236-42. PubMed ID: 16543605
[TBL] [Abstract][Full Text] [Related]
19. The Tetrazole VT-1161 Is a Potent Inhibitor of Trichophyton rubrum through Its Inhibition of T. rubrum CYP51.
Warrilow AGS; Parker JE; Price CL; Garvey EP; Hoekstra WJ; Schotzinger RJ; Wiederhold NP; Nes WD; Kelly DE; Kelly SL
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28483956
[TBL] [Abstract][Full Text] [Related]
20. Azole binding properties of Candida albicans sterol 14-alpha demethylase (CaCYP51).
Warrilow AG; Martel CM; Parker JE; Melo N; Lamb DC; Nes WD; Kelly DE; Kelly SL
Antimicrob Agents Chemother; 2010 Oct; 54(10):4235-45. PubMed ID: 20625155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
